Allergic bronchopulmonary mycosis induced by pembrolizumab for bladder cancer: A case report
{{output}}
Pembrolizumab is an immune checkpoint inhibitor (ICI) of programmed cell death-1 category, used for treating various types of cancer. ICIs can sometimes result in immune-related adverse events. Allergic bronchopulmonary mycosis (ABPM) induced by ICI has rarely... ...
